While unable to comment on specific cases, PBD Biotech, developer of Actiphage®, offers the following clarification:
PBD Biotech are currently in the process of validating the Actiphage (Phage-PCR) test for the detection of Mycobacterium bovis (bovine TB) and Mycobacterium paratuberculosis (Johne’s disease) in cattle blood, and this is our primary focus.
Unlike other technologies the Actiphage® test does not measure an immune response, but specifically detects the DNA extracted from live Mycobacteria present in circulating blood as a marker of disease.
At this stage we have limited proof of concept data that the test can be applied to over 20 species, including humans and alpacas, and remain open to collaboration with researchers and regulators across the globe who want to advance the science and understanding of these devastating diseases.
